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MaThis paper describes some important controversies regarding the current state of clinical trials research in cardiology.
Topics covered include the inadequacy of trial research on medical devices, problems with industry-sponsored trials, the
lack of head-to-head trials of new effective treatments, the need for wiser handling of drug safety issues, the credibility
(or lack thereof) of trial reports in medical journals, problems with globalization of trials, the role of personalized
(stratiﬁed) medicine in trials, the need for new trials of old drugs, the need for trials of treatment withdrawal, the
importance of pragmatic trials of treatment strategies, and the limitations of observational comparative effectiveness
studies. All issues are illustrated by recent topical trials in cardiology. Overall, we explore the extent to which clinical
trials, as currently practiced, are successful in meeting society’s expectations. (J Am Coll Cardiol 2014;64:1615–28)
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authorities. Indeed, innumerable important advances
in patient care, including the abandonment of bio-
logically plausible but ineffective or unsafe treat-
ments, have been based upon rigorous scrutiny from
major pivotal RCTs.
Despite such successes, it is relevant to ask to what
extent the whole ﬁeld of clinical trials research as
currently practiced does, in fact, meet society’s
needs.
Here we focus on several topical controversies
from a cardiovascular (CV) perspective, each illus-
trated by recent clinical trials. The aim throughout is
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PLACEBO EFFECT AND MEDICAL DEVICES
Until the recent SYMPLICITY HTN-3 (Renal Denerva-
tion in Patients With Uncontrolled Hypertension) trial
revealed its negative ﬁndings (1), there was much
collective expectation that renal denervation could
be a very effective intervention in resistant hyper-
tension. In 2009, SYMPLICITY 1, an uncontrolled
trial of 45 patients, found a marked decrease in sys-
tolic blood pressure (SBP) after 12 months (2). SYM-
PLICITY 1 was subsequently expanded to report a
mean 22 mm Hg decrease in SBP at 6 months in 86
patients (3). In 2010, SYMPLICITY 2, a randomized,
unblinded, controlled trial in 100 patients was
equally positive, with mean 6-month SBP reductionsropical Medicine, London, United Kingdom; and the
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
graft
CI = conﬁdence interval
CV = cardiovascular
FDA = U.S. Food and Drug
Administration
GPI = glycoprotein IIb/IIIa
inhibitor
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
SBP = systolic blood pressure
STEMI = ST-segment elevation
myocardial infarction
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1616of 32 and 1 mm Hg, respectively, in the renal
denervation and control arms (4).
Because of the recognized potential for
bias in these studies, to obtain more rigorous
evidence and, speciﬁcally, to satisfy the U.S.
Food and Drug Administration’s (FDA’s)
regulatory requirements, SYMPLICITY 3 was
a larger RCT comparing renal denervation
with a sham procedure control group in a 2:1
randomization ratio: patients and those
assessing outcomes were blinded as to who
got what (1). In the renal denervation (n ¼
364) and sham procedure (n ¼ 171) arms,
mean 6-month SBP reductions were 14 and 12
mm Hg, respectively: a nonsigniﬁcant dif-
ference of only 2 mm Hg. The difference be-tween SYMPLICITY 3 and the earlier ﬁndings is very
marked (Figure 1).
Advocates of renal denervation are exploring
possible deﬁciencies in SYMPLICITY 3. Did patients
not truly have resistant hypertension? Are there
speciﬁc subsets of patients with hypertension who
would beneﬁt? Was drug use different in the 2 arms?
Were operators too inexperienced? Are better devices
now available? The obvious explanation is that renal
denervation appears to be insufﬁciently effective in
reducing SBP in this population and that previous
ﬁndings reﬂect a substantial placebo effect, regres-
sion to the mean, and the possibility that patients
with “refractory hypertension” became adherent to
drug therapy once enrolled into the trial. Additional
trials would be helpful in establishing the role (or lack
thereof) for renal denervation in hypertension.
However, the story thus far indicates that the hype of
an illusory breakthrough in management of resistant
hypertension was perpetuated by inadequately-
designed RCTs, which gave exaggerated ﬁndings
and did not take into account the power of the
placebo.
Another excellent example of the placebo effect
arises from trials of permanent pacemakers in pa-
tients with vasovagal syncope (5). A meta-analysis of
9 trials demonstrated that in unblinded studies,
active pacing resulted in a striking reduction in
recurrent syncope (odds ratio: 0.09, 95% conﬁdence
interval [CI]: 0.04 to 0.22). Nonetheless, when pa-
tients with permanent pacemakers were blinded as to
whether or not the pacing modes were activated,
there was no signiﬁcant effect (odds ratio: 0.83;
95% CI: 0.41 to 1.70).
These experiences have important wider implica-
tions for research into medical devices. Of particular
note are the very undemanding requirements for
medical device approval in Europe (6). The CE Markneeded to market a device in the European Commu-
nity does not usually require evidence from RCTs;
renal denervation is 1 such example. Relatively small,
uncontrolled studies focusing on performance objec-
tives, rather than valid evidence of efﬁcacy and safety,
are assessed by Notiﬁed Bodies, who are widely
recognized as lacking appropriate scientiﬁc objectiv-
ity. Consequently, such an easy, nonrigorous approval
process carries risks that patients could be exposed to
ineffective and/or unsafe devices.
There is understandable frustration in the United
States that new devices get approved much more
slowly than in Europe. Thus, for coronary stents and
transcatheter aortic valve replacements, there is the
perception that U.S. patients have a substantial delay
in access to effective new devices compared with
Europeans. Although there may be room for a more
expedited approval process within the FDA, critics of
the current approach need to recognize that efﬁcacy
and safety can be truly determined only after the
FDA-required RCTs are performed. The real problem
lies in Europe: there is a need for radical reform of
how medical devices get approved in Europe, both in
terms of the currently inadequate process and the
need for well-designed RCTs to be a fundamental part
of the mandated evidence base.
PROBLEMS WITH PHARMACEUTICAL TRIALS:
THE BIVALIRUDIN EXPERIENCE
The results of the HEAT PPCI (How Effective are
Antithrombotic Therapies in Primpary PCI) trial (7),
which compared bivalirudin with unfractionated
heparin in 1,892 primary percutaneous coronary
intervention (PCI) patients followed for 28 days,
provoked considerable debate. The primary compos-
ite outcome (death, stroke, reinfarction, or un-
planned target lesion revascularization) was higher in
the bivalirudin group (8.7% vs. 5.7%; p ¼ 0.01), as was
stent thrombosis (3.4% vs. 0.9%; p ¼ 0.001), whereas
there was no evidence of a difference in major
bleeding (3.5% vs. 3.1%; p ¼ 0.59). The use of glyco-
protein IIb/IIIa inhibitors (GPIs) was similarly low in
both groups (13.5% vs. 15.5%).
This apparent inferiority of bivalirudin seems to
contradict evidence from 3 previous trials, each
claiming superiority of bivalirudin alone versus
heparinþGPI. The ACUITY (Acute Catheterization and
Urgent Intervention Triage strategy) trial (8) in 13,819
patients with acute coronary syndrome showed biva-
lirudin to be noninferior for 30-day composite
ischemia (death, myocardial infarction, and revascu-
larization) (7.8% vs. 7.3%) and superior for major
bleeding (3.0% vs. 5.7%). The HORIZONS-AMI
SYMPLICITY 1
SYMPLICITY 2
SYMPLICITY 3
-10 0 10 20 30 40
Mean Reduction in SBP-mm Hg (and 95% CI)
denervation
denervation
denervation
unblinded control
sham control
FIGURE 1 A Comparison of Changes in SBP at 6 Months in
3 Trials of Renal Denervation
CI ¼ conﬁdence interval; SBP ¼ systolic blood pressure.
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1617(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial (9) in
3,602 primary PCI patients had coprimary 1-year
endpoints of major bleed (5.8% vs. 9.2%; p < 0.0001)
and net adverse clinical events (15.6% vs. 18.3%;
p ¼ 0.02). The EUROMAX (European Ambulance
Acute Coronary Syndrome Angiography Trial) (10) in
2,218 primary PCI patients had a primary 30-day
composite endpoint of death and major bleed (2.6%
vs. 6.0%; p < 0.0001). Reinfarction (1.7% vs. 0.9%,
p ¼ 0.08) was removed from this primary outcome
after the trial had started. In all of these industry-
sponsored trials, there was a high use of GPI in the
heparin arm (97% in the ACUITY, 94.5% in the
HORIZONS-AMI, and 69.1% in the EUROMAX trial),
and this addition of GPI to heparin is what provokes
the increased bleeding risk.
Thus, routine practice should now entail much
lesser use of GPI (more as a bailout rather than up
front), as is reﬂected in the HEAT-PPCI trial. This trial
was investigator-initiated and included all eligible
patients in a single center. It is the only head-to-head
comparison of bivalirudin and heparin with equal,
appropriately low GPI use. It has its critics. Was the
bivalirudin dosage too low? Was the delayed consent
process ethically appropriate (an important debate,
but one that does not affect the actual results)? The
main point here is that industry-sponsored trials to
date have not directly answered the pivotal question:
how does bivalirudin compare with heparin in the
context of equal and appropriate background GPI
use? The HEAT-PPCI trial ﬁndings indicate an urgent
need for a further deﬁnitive RCT of this issue.On a more general note, the clinical trial programs
that industry undertakes are understandably dedi-
cated to getting their product licensed by regulators
(e.g., the FDA and European Medicines Agency [EMA])
and subsequently approved by health technology as-
sessments, such as the National Institute for Health
and Care Excellence in the United Kingdom. This
process does not necessarily deliver RCTs that are in
the best public interest. DeMets and Califf (11) assert in
their historical perspective on clinical trials innovation
and leadership that, “a better balance between com-
mercial interests and public health is critically
needed.” For instance, in chronic heart failure, it is
common to evaluate any newdrug in a pivotal placebo-
controlled trial in addition to the multidrug regimens
that patients already receive. Speciﬁcally, the SHIFT
(Systolic Heart Failure Treatment with Ivabradine)
trial (12) of ivabradine was placebo-controlled, with
beta-blocker therapy as part of such background
therapy. A head-to-head comparison of ivabradine
versus beta-blocker (both lower heart rate) would be of
great interest, but commercial sponsorship of such a
trial appears unlikely. These problems are not neces-
sarily due to company policy, but may well arise
because regulators require placebo-controlled trials
upon a background of current standard therapy.
THE LACK OF HEAD-TO-HEAD TRIALS:
NEW ANTICOAGULANTS
In atrial ﬁbrillation, several large trials have compared
new anticoagulants against warfarin: the RE-LY
(Randomized Evaluation of Long Term Anticoagu-
lant Therapy) (13), ROCKET-AF (Rivaroxaban Once
Daily Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibril-
lation) (14), ARISTOTLE (Apixaban for the Reduction
in Stroke and Other Thromboembolic Events in
Atrial Fibrillation) (15), and ENGAGE (Effective Anti-
coagulation with Factor Xa Next Generation in Atrial
Fibrillation) (16) trials studied dabigatran, rivarox-
aban, apixaban, and edoxaban, respectively. Each
trial had stroke and systematic embolism as the
composite primary endpoint and major bleeding as
the key safety endpoint. Their ﬁndings are summa-
rized in Figure 2, with all estimates (and 95% CIs) be-
ing hazard ratios for new anticoagulant versus
warfarin. Collectively, they tell a success story
whereby new anticoagulants tend overall to reduce
the risk of both the primary endpoint and major
bleeding. The next logical question is whether there
are real differences in their efﬁcacy and safety, and, if
so, which new anticoagulant appears to be best? The
indirect evidence is plotted in Figure 2.
Dabigatran 150 mg
Dabigatran 110 mg
Rivaroxaban
Apixiban
Endoxaban 60 mg
Endoxaban 30 mg
Dabigatran 150 mg
Dabigatran 110 mg
Rivaroxaban
Apixiban
Endoxaban 60 mg
Endoxaban 30 mg
Stroke and Systemic Embolism
0.4 0.6 0.8 1.0 1.2 1.4
0.4 0.6 0.8 1.0 1.2 1.4
Hazard Ratio (and 95% CI) Versus Warfarin
Hazard Ratio (and 95% CI) Versus Warfarin
Major bleed
FIGURE 2 Comparisons of 4 New Anticoagulants Versus
Warfarin in the RE-LY, ROCKET-AF, ARISTOTLE, and
ENGAGE Trials
CI ¼ conﬁdence interval.
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1618At face value, the higher dose of dabigatran has the
greatest reduction in risk of stroke and systemic em-
bolism, whereas apixaban has similar efﬁcacy and
fewer major bleeds. But, these assertions are unreli-
able because they rely on indirect comparisons via
warfarin across different trials. The trials differ in
patient selection, outcome deﬁnitions, blinding
(RE-LY was not double-blind, and does that matter?),
and the degree of international normalized ratio con-
trol of warfarin, and it is unclear to what extent these
issues affect the validity of indirect comparisons (17).
Unfortunately, there appears to be no prospect of
a head-to-head trial of 2 (or more) of these new an-
ticoagulants. Thus, which anticoagulant gets used in
practice depends on faster regulatory approval, suc-
cessful marketing, and costs rather than on reliable
estimates of relative efﬁcacy and safety. We cannot
expect industry to fund these head-to-head trials, so
public funds (e.g., the National Heart, Lung, and
Blood Institute) are required. Pathways to motivate,
fund, and activate such pragmatic head-to-head tri-
als need to be created. A commendable example
is the ISAR-REACT (Intracoronary Stenting andAntithrombotic Regimen: Rapid Early Action for
Coronary Treatment) 5 trial (18) comparing ticagrelor
and prasugrel in patients with an acute coronary
syndrome. How can we stimulate such initiatives to
become a more common feature of post-licensing
evaluation of effective new agents?
THE CHOICE OF DOSE IN
PIVOTAL DRUG TRIALS
A key issue is the choice of dose for each drug in
a pivotal Phase III trial. The RE-LY trial in atrial
ﬁbrillation is commendable for having studied 2
different doses of dabigatran (150 and 110 mg). The
former appears more efﬁcacious and the latter has
less bleeding: a logical ﬁnding leaving clinicians an
appropriate choice as to what is best for the individ-
ual patient. Both doses are approved in Europe.
However, in the United States, the FDA did not
approve the 110 mg dose, opting for 75 mg instead.
The more general point here is that any comparison
of drugs is on the basis of the speciﬁc doses chosen for
their pivotal trials, and the potential for a wrong (or
somewhat inferior) choice of dose is always present.
For instance, in testing such anticoagulants in patients
with an acute coronary syndrome, the APPRAISE 2
(Apixaban for Prevention of Acute Ischemic Events – 2)
(19) trial of apixaban was terminated prematurely for
safety reasons (perhaps because of too high a dose),
whereas the 3-arm ATLAS ACS 2 (Anti-Xa Therapy to
Lower Cardiovascular Events in Addition to Standard
Therapy in Acute Coronary Syndrome) (20) of rivar-
oxaban compared 2 doses against placebo, showing
that the lower dose appeared superior.
Across all pharmaceutical research, getting the dose
right for the pivotal phase III trial of a new product is a
major challenge. Wrong choices can have disastrous
consequences, both for patients and for a promising
drug. A wiser admission of the remaining uncertainty
after the phase II trial evidence is in may justify the
need for more than 1 dose choice in phase III (although
the problem of increased trial size is an issue). Another
risk is that, in the race to seek faster licensing approval,
phase III trials may be initiated before reliable evi-
dence of correct dose choice exists. For instance, did
the excess mortality of moxonidine in chronic heart
failure (21) arise because of a hasty choice of dose in
the phase III trial before phase II was completed?
THE NEED FOR BETTER HANDLING OF
DRUG SAFETY: ANTIDIABETIC AGENTS
Potential safety problems with a drug are often not
handled wisely. On the one hand, companies may
conﬁdently assert that their drug is safe; on the other
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1619hand, activists who are convinced that a drug is
harmful may go to great lengths to promote their
case. This can escalate into undue media attention
(scare stories) and political involvement, whereby the
pressures on regulators make it difﬁcult to achieve
a calm, objective assessment of the totality of evi-
dence. A case in point concerns the potential CV risks
associated with rosiglitazone in diabetic patients. A
meta-analysis published in 2007 (22) reported a 42%
increased risk of myocardial infarction (p ¼ 0.04) in
patients taking rosiglitazone versus control subjects.
The evidence was weak, it was from a heterogeneous
mix of mostly small trials with short-term follow-up,
and myocardial infarction events were not validated.
The journal Nature referred to this meta-analysis as
“a rushed and incomplete examination,” but it
engendered such a high proﬁle that the FDA had to
instigate urgent inquiries into rosiglitazone’s CV
safety.
The RECORD (Rosiglitazone Evaluated for Cardio-
vascular Outcomes and Regulation of Glycaemia
Diabetes) trial (23) provided the only speciﬁcally-
designed randomized evidence on the topic, as pre-
viously requested by the European Medical Agency.
Its primary ﬁndings of no overall effect of rosiglita-
zone on all CV hospitalizations and deaths were
accompanied by inconclusive evidence regarding
myocardial infarction. The trial was not double-blind,
and accusations that it was open to bias held sway in
the FDA hearing. The Lancet’s caution that “alarmist
headlines and conﬁdent assertions help nobody” was
not the predominant mood of the time. However, 3
years later (in 2013), an FDA panel reassessment
concluded, “rosiglitazone is not associated with
excess myocardial infarction.” This relied on an in-
dependent readjudication of events in the RECORD
trial, with no change in its conclusions. In hindsight,
this evolving debate was too focused on the risk of
myocardial infarction. The RECORD trial found
highly signiﬁcant excesses of “apparent” heart failure
events (perhaps due to ﬂuid retention of uncertain
signiﬁcance) and bone fractures on rosiglitazone
compared with control (hazard ratios: 2.10 and 1.57,
respectively), but these concerns received little
attention in the FDA process. In Europe, rosiglitazone
was suspended in 2010 because its beneﬁts no longer
outweigh its risks, a verdict based on the overall drug
proﬁle.
Largely led by this rosiglitazone story, the FDA
guidance for industry on cardiovascular risk in new
antidiabetic agents (24) mandated evidence of car-
diovascular safety for any such drug. For licensing
approval, one needed to rule out an 80% excess
cardiovascular risk, to be followed by a subsequentlarge cardiovascular safety trial to rule out a 30%
excess risk. Thus, large noninferiority trials of each
such drug versus placebo are in progress, usually with
a composite primary endpoint of CV death, myocardial
infarction, and stroke, and recruitment of diabetic
patients at high risk of CV events. It is curious
that heart failure is not included in the primary
endpoint, given its apparent excess on rosiglitazone.
Two such trials have now been completed, both
concerning gliptins, a different class of drugs from
the glitazones. The SAVOR–TIMI 53 (Saxagliptin
Assessment of Vascular Outcomes Recorded in Pa-
tients with Diabetes Mellitus–Thrombolysis In Myo-
cardial Infarction 53) trial of saxagliptin (25) and
the EXAMINE (Examination of Cardiovascular Out-
comes with Algorithms versus Standard of Care) trial
of alogliptin (26) showed no effects on the primary
endpoint. However, both trials had a numerical
excess of heart failure hospitalizations compared
with placebo: hazard ratios were 1.27 (95% CI: 1.07 to
1.51) and 1.07 (95% CI: 0.79 to 1.46), respectively, the
former (saxagliptin) was statistically signiﬁcant
(p ¼ 0.007). A cautious interpretation is appropriate:
heart failure was one of several secondary hypothe-
ses and the interaction test comparing the drugs’
heart failure effects (via an indirect comparison) is
not signiﬁcant. Thus, any claim that saxagliptin alone
causes heart failure is unwarranted. The results of
the TECOS (Trial Evaluating Cardiovascular Out-
comes with Sitagliptin) of sitagliptin (27) are awaited
with interest.
We now recognize that cardiovascular safety is a
key issue in the development and use of antidiabetic
drugs; thus, demonstration of glycemic efﬁcacy alone
is not sufﬁcient evidence for regulatory approval by
both the FDA and the EMA. The more ﬂexible
approach of the latter is, perhaps, more appropriate
than the FDA’s formal noninferiority trial strictures.
What is sadly lacking is an antidiabetic drug that
actually reduces CV risk.
There have been other drug safety concerns initi-
ated by claims based on weak evidence. For instance,
the associations between calcium-channel blockers
and myocardial infarction, ezetimibe and cancer, and
angiotensin-receptor blockers and cancer all invoked
much research and/or expert investigation leading to
conclusions of no safety problem. Rofecoxib was
rightly associated with an increased risk of myocar-
dial infarction, although initial relative risk estimates
were higher than those subsequently found in more
substantive meta-analysis. This is likely to be a
recurring theme. That is, concerns are stimulated
because initial claims made on the basis of limited
evidence are prone to exaggeration. More substantial
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1620evidence to follow usually demonstrates regression to
the truth. The challenge is whether that “truth” is a
more modest risk or none at all.
In the case of rofecoxib, the risk of myocardial
infarction appears to be real, but whether that justi-
ﬁed a complete ban is open to debate. Given its
marked value in pain relief for patients at low risk of
myocardial infarction, a judgment could be made that
the low excess absolute risk would be outweighed by
the drug’s undoubted efﬁcacy.
Two big problems concerning safety signals are: 1)
because they are often unanticipated, quality data on
harms may not be collected uniformly across trials;
and 2) trial exclusion criteria may remove some pa-
tients for whom the drug is less safe, whereas such
patients subsequently become exposed to the drug in
routine practices. This makes post-licensing surveil-
lance of drug safety an important issue.
CREDIBILITY OF CLINICAL TRIAL REPORTS
IN MEDICAL JOURNALS
Much attention has been paid by trialists, editors,
referees, and guidelines (e.g., CONSORT [28]) to
ensure that clinical trial reports in medical journals
are of high quality, and improvements have been
made over the years. However, we feel that com-
mercial pressures and investigator enthusiasm to
assert positive claims combined with publication
bias, whereby more “exciting” ﬁndings are more
likely to reach major journals, means that the clinical
trials literature still has an overall tendency toward
exaggerated claims. We explore this with a few recent
examples.
The CoreValve trial (29) comparing transcatheter
aortic valve replacement with surgery concluded that
transcatheter aortic valve replacement “was associ-
ated with a signiﬁcantly higher rate of survival at 1
year.” The 1-year mortality rates were 14.2% versus
19.1%, and the investigators used an unconventional
1-sided signiﬁcance test to claim p ¼ 0.04. A con-
ventional analysis would report a difference of 4.9%
with a 95% CI from 10.3% to þ0.5%, p ¼ 0.08. These
data are suggestive of a potential survival beneﬁt, but
the claim by the investigators is overassertive.
A common scenario is when a major clinical trial
produces a disappointing neutral ﬁnding for the
overall pre-deﬁned primary endpoint, but inves-
tigators are tempted to make other positive claims
in secondary endpoints and/or subgroup analyses.
For instance, the BEAUTIFUL (Morbidity-Mortality
Evaluation of Ivabradine in Patients with Coronary
Disease and Left Ventricular Dysfunction) trial (30) of
ivabradine versus placebo in patients with coronarydisease and left ventricular systolic dysfunction had
almost identical incidence rates for the composite
primary endpoint (CV death, myocardial infarction,
and congestive heart failure) (p ¼ 0.94). The inves-
tigators proceeded to emphasize the difference in
myocardial infarction only in the subgroup with heart
rate $70 beats/min: 3.1% versus 4.9% (p ¼ 0.001),
highlighting this ﬁnding in both the abstract and
conclusions sections. We feel that it was inappro-
priate to assert such a positive claim. It is legitimate
to document such a secondary ﬁnding as data explo-
ration and hypothesis generating, but it should not
affect the overall negative conclusions of the trial.
The CURRENT OASIS 7 (Clopidogrel and Aspirin
Optimal Dose Usage to Reduce Recurrent Events) trial
(31,32) compared standard versus double-dose clopi-
dogrel in patients with an acute coronary syndrome.
A Lancet paper concluded, “in patients undergoing
PCI, double dose was associated with a reduction in
CV events” (31). The same weekend, a paper in the
New England Journal of Medicine concluded, “in pa-
tients referred for an invasive strategy, there was no
signiﬁcant difference between double-dose and
standard dose” (32). This apparent contradiction in
ﬁndings came about because the Lancet paper con-
cerns a selected subgroup of 17,232 patients who
received PCI: the primary composite endpoint of CV
death, myocardial infarction, and stroke within 30
days occurred in 3.9% and 4.5% of the double- and
standard-dose groups (p ¼ 0.039). The New England
Journal of Medicine paper included all 25,087 patients
with a primary endpoint comparison of 4.2% versus
4.4% (p ¼ 0.37). The interaction test (p ¼ 0.03 for
those receiving PCI vs. the rest) suggests a possible
heterogeneity of treatment effect, but such second-
ary evidence favoring double-dose clopidogrel is
weak. The Lancet paper is problematic because it did
not make explicit that it was a subgroup ﬁnding, that
receiving PCI is an improper subgroup in the sense
that it was only determined after randomization,
and that such a qualitative interaction (primary
endpoint 4.2% vs. 4.9% in the opposite direction for
the 7,855 patients not receiving PCI) is rare and
implausible.
The SHIFT trial (12) of ivabradine versus placebo in
chronic heart failure reported very strong evidence of
a reduction in incidence of the primary endpoint, CV
death and heart failure hospitalization: hazard ratio:
0.82 (p < 0.0001). But, there was an interaction with
baseline heart rate, so what appeared in the Lancet
as an overall positive ﬁnding was a more restricted
approval by the EMA: “ivabradine is indicated in
chronic heart failure patients. whose heart rate
is $75 bpm.”
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1621An overall picture emerges regarding reporting
subgroup ﬁndings and other secondary analyses.
They should be reported in a cautious spirit of
exploratory data analysis, with authors and journals
exercising restraint, especially when the primary
overall trial result is not positive. Conversely, when
the overall conclusion is positive, secondary ﬁndings
(e.g., on subgroups, adverse events) may appropri-
ately place restrictions on the future population of
patients who truly beneﬁt from the new treatment.
One concern is that the most important trials are
processed as “fast-track” publications, whereby the
time from database lock to online release in a major
journal is made as short as possible. We fear that such
breakneck speed combined with the very limited
journal space can occasionally be detrimental to the
quality of publication. From a regulatory perspective,
journal publications are of limited value because they
report such a small, selected subset of ﬁndings
compared with the much more extensive regulatory
dossiers.
THE GLOBALIZATION OF RCTs:
DOES GEOGRAPHY MATTER?
Many major trials are multiregional, both to get the
large sample size required and to achieve a more
globally representative patient population, especially
when approval is sought from regulators in different
parts of the world. The problem is that the ability to
recruit patients can differ markedly across regions:
Eastern European centers commonly recruit faster
than centers in the United States and Western
Europe. This raises concerns over whether such
geographic disparities in recruitment affect the va-
lidity of the overall trial ﬁndings, especially if the
future population for the approval and use of new
expensive treatment lies in relatively wealthy coun-
tries. Although one is obligated to explore trial data
for geographic differences in treatment effect, this
is a particularly tricky form of subgroup analysis
that lacks statistical power. Hence, real geographic
heterogeneity may well go undetected. On the other
hand, any observed statistically signiﬁcant hetero-
geneity across countries or regions is liable to be an
exaggeration of the truth.
The TOPCAT (Treatment of Preserved Cardiac
Function Heart Failure with an Aldosterone Antago-
nist) trial (33) of spironolactone in preserved ejection
fraction heart failure is an intriguing example of the
challenges faced in conducting and interpreting
geographic differences. Overall, the trial showed a
modest nonsigniﬁcant trend toward the superiority
of spironolactone versus placebo: the compositeprimary endpoint (CV death, heart failure hospitali-
zation, and resuscitated cardiac arrest) had a hazard
ratio: 0.89 (95% CI: 0.77 to 1.04), with p ¼ 0.138. To
facilitate patient recruitment in this National In-
stitutes of Health–funded trial, nearly one-half of the
patients (1,678 of 3,445) were in Russia and Georgia.
But, the incidence rate of the primary endpoint in the
placebo group in these 2 countries was less than one-
ﬁfth of that in the other Western countries (United
States, Canada, Argentina, and Brazil). Hazard ratios
for the primary endpoint were 1.10 in Russia and
Georgia and 0.82 in the rest. The latter achieves sta-
tistical signiﬁcance (p < 0.05), but the formal test for
heterogeneity in hazard ratios across regions is not
statistically signiﬁcant (interaction p ¼ 0.12). It is not
clear exactly why ﬁndings in Russia and Georgia are
so discrepant with the rest: is it patient selection,
healthcare systems, patterns of follow-up, or data
quality issues that contribute? Overall, this trial is a
valuable lesson that enhancing recruitment in other
regions may not necessarily deliver generalizable
ﬁndings and can sometimes hamper the ability to
detect important treatment differences.
The PLATO (Study of Platelet Inhibition and Pa-
tient Outcomes) (34) in patients with acute coronary
syndrome is a very different scenario, where apparent
geographic heterogeneity cast doubt on whether the
overall trial result was generalizable to patients in the
United States. Compared with clopidogrel, ticagrelor
had fewer primary endpoints (CV death, myocardial
infarction, and stroke), with an overall hazard ratio:
0.84 (95% CI: 0.77 to 0.92; p < 0.001). However, in
North America, the hazard ratio was 1.25 (95% CI:
0.93 to 1.67) and the test for heterogeneity across 4
regions had an interaction p ¼ 0.05. Furthermore, the
post-hoc interaction test comparing the United States
with all other countries combined had p ¼ 0.009.
The search across more than 50 potential explanatory
factors for this geographic anomaly revealed that
differences in the maintenance dose of aspirin could
be relevant: high-dose aspirin ($300 mg) was
administered to 54% of U.S. patients and to <2% of
non-U.S. patients. The primary endpoint hazard ra-
tios for ticagrelor versus clopidogrel were 1.45 and
0.79 in patients on high- and low-dose aspirin,
respectively, interaction p ¼ 0.0006. After much
deliberation, the FDA approved ticagrelor, but with a
boxed warning, “use of ticagrelor with aspirin doses
exceeding 100 mg/day decreases its effectiveness.”
However, the main lesson is not about ticagrelor as
such, but is to get American practitioners to no longer
prescribe high doses of aspirin in such patients. A
valid alternative viewpoint is that the geographic
anomaly in PLATO could have been due to the play of
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confounded with region. Such trials are not powered
to address potential geographic heterogeneity, and
these post-hoc questions can lead to spurious ﬁnd-
ings (35).
Overall, regional disparities in a global RCT may
arise for several reasons: racial/genetic issues; dif-
ferences in background therapy, healthcare systems,
and recruitment patterns; and variation in the quality
of trial conduct and data quality. Thus, the greater
ease in reaching recruitment targets is offset by these
potential complications: caution is warranted.
THE ROLE OF PERSONALIZED (STRATIFIED)
MEDICINE IN RCTs
When a report of an RCT reaches a positive conclu-
sion regarding a new treatment’s beneﬁt, this may
not necessarily apply equally to all eligible patients.
Although the perils of subgroup analysis are well
known (and mentioned earlier in this review) a
treatment’s efﬁcacy and safety still need to be con-
sidered in the context of the individual patient’s risk
proﬁle. It is informative to document the absolute
treatment differences in the primary endpoint strat-
iﬁed according to patient risk status.
For instance, the EMPHASIS (Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart
Failure) trial (36) in heart failure patients with mild
symptoms compared eplerenone with placebo and
found a highly signiﬁcant reduction in the primary
endpoint, heart failure hospitalization or CV death:
hazard ratio: 0.63 (p < 0.0001), with no evidence of
any subgroup interactions. Grouping patients into
low-, mid-, and high-risk strata based on a risk score
revealed incidence reductions on eplerenone of
2.0, 6.8, and 15.2 primary events per 100 patient-
years, respectively. Thus, the absolute treatment
beneﬁt is much greater in patients with a poorer
prognosis. This approach should be applied more
widely to major RCTs, and could better focus atten-
tion on high-risk patients, whose absolute beneﬁt is
often much greater.
The individual patient’s appropriate therapeutic
choice becomes more challenging when treatments
differ both in efﬁcacy and in safety, but in opposite
directions. For instance the TRITON–TIMI 38 (TRial
to assess Improvement in Therapeutic Outcomes
by optimizing platelet InhibitioN with prasugrel–
Thrombolysis In Myocardial Infarction 38) (37) in
patients with acute coronary syndrome undergoing
PCI found prasugrel superior to clopidogrel for the
ischemic primary endpoint, CV death, myocardial
infarction, and stroke (9.1% vs. 11.5%, respectively)but inferior to clopidogrel for Thrombolysis In
Myocardial Infarction major or minor bleed (5.0% vs.
3.7%, respectively). For each patient, the relative
merits of prasugrel and clopidogrel should include
consideration of the tradeoff between efﬁcacy and
safety, taking account of their individual risks of
ischemia and bleeding. Salisbury et al. (38) created
multivariable predictive models for ischemic risk and
bleeding risk, including some interactions with
treatment (e.g., prasugrel’s bleeding excess was more
pronounced in older patients). The consequence was
an ability to predict for any patient whether prasugrel
had a net beneﬁt over clopidogrel: this appeared to
be true for 42% of patients in the TRITON–TIMI 38
trial. In general, trialists need to do a better job of
providing data and tools to apply results to indivi-
duals, especially when beneﬁts and risks have dif-
fering balance points across the patient population.
These ideas also apply to major trials comparing 2
different doses of a new drug. In the RE-LY (13) and
ENGAGE (16) trials of dabigatran (150 mg vs. 110 mg)
and edoxaban (60 mg vs. 30 mg) in atrial ﬁbrillation,
the higher doses were more effective in stroke pre-
vention, but also caused more major bleeds. For the
RE-LY trial, Eikelboom et al. (39) concluded, “the
similar overall beneﬁts of the two doses versus
warfarin support individualizing the dose based on
patient characteristics and physician and patient
preferences.” We need further quantitative research
to facilitate this concept.
A more provocative use of the term “personalized
medicine” concerns the search for new biomarker- or
genotype-speciﬁc treatments (40). Can we ﬁnd a
biomarker that, if positive, indicates a poor patient
prognosis (e.g., pro–B-type natriuretic peptide in
heart failure) and that also facilitates a new, targeted
treatment that is especially effective in biomarker-
positive patients? For instance, in some acute coro-
nary syndrome trials, therapies work well in
troponin-positive patients but not at all in others.
There have been successes in cancer research and
treatment in this form of personalized medicine (e.g.,
herceptin is speciﬁc to HER2-positive breast cancer),
but we are skeptical whether there will be major
breakthroughs in cardiology. Mutations are central to
the pathophysiology of cancers, but not to most CV
diseases. Nevertheless, the ideas might apply to
monogenetic CV diseases like hypertrophic cardio-
myopathy, or to mutations affecting clopidogrel or
warfarin sensitivity.
The huge multiplicity of potential biomarkers
being investigated and the lack of clarity on what
“biomarker positive” means carry a risk of pursuing
seemingly attractive, but false positive leads. Also,
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the hope for a new “magic bullet” biomarker needs to
be seen in the context of the complex of other, already
established risk factors. Time will tell whether any
biomarker-speciﬁc targeted treatments emerge from
rigorously-conducted RCTs in cardiology.
THE NEED FOR NEW TRIALS OF OLD DRUGS:
THE CASE OF BETA-BLOCKERS
Once a drug (or class of drugs) has achieved regula-
tory approval there may be some post-approval trials
(e.g., safety trials) supported by the sponsor, but
sponsors do not usually have any long-term plans for
future clinical trials research. Indeed, once the patent
duration approaches (and passes) its end, sponsors
have even less motivation to stimulate and fund new
research. Yet, new, important questions that would
be best answered by initiating new clinical trials may
arise many years after any effective class of drugs ﬁrst
came into use. The dilemma is how to get such trials
publicly funded and activated, given the inevitable
lack of commercial sponsorship. We illustrate this
problem with 3 outstanding issues concerning beta-
blockers where new RCTs would be of great value.
The role of beta-blockers after a myocardial
infarction was well studied years ago, but those trials
were all done before primary PCI became the standard
practice for ST-segment elevation myocardial infarc-
tion (STEMI) patients. Thus, an interesting unre-
solved issue is whether intravenous metoprolol
administered before reperfusion in STEMI patients
can enhance prognosis. A pilot trial, METOCARD-
CNIC (Effect of Metoprolol in Cardioprotection Dur-
ing an Acute Myocardial Infarction) (41), showed
reduced infarct size and improved left ventricular
function compared with untreated control subjects.
A longer-term, double-blind, placebo-controlled RCT
of intravenous metoprolol administered before the
primary PCI is now needed. Because prevention of
post-infarction heart failure is the goal, the proposed
primary composite endpoint is heart failure hospi-
talization and cardiac death over 2 years of follow-up,
requiring a trial of around 4,000 patients.
An ongoing controversy concerns the value (or lack
thereof) of beta-blocker treatment in patients un-
dergoing noncardiac surgery. Previous guidelines,
both in Europe and in the United States, recom-
mended beta-blockers in this setting, but 2 key trials
have since been discredited because of alleged sci-
entiﬁc misconduct. Furthermore, POISE (Periopera-
tive Ischemic Evaluation Study) (42), the largest
remaining trial comparing metoprolol versus placebo,
is controversial, with a 30% decrease in nonfatalmyocardial infarction (p < 0.001) contrasting with a
33% increase in total mortality (p ¼ 0.03), perhaps
because the beta-blocker dose was too high. Meta-
analyses provide inconclusive evidence on the
topic. The new European Society of Cardiology/Eu-
ropean Society of Anaesthesiology guidelines on
noncardiac surgery (43) conclude that, “high priority
needs to be given to new randomized clinical trials to
better clarify which patients derive beneﬁt from beta-
blocker therapy in the preoperative setting, and to
determine the optimal method of beta-blockade.”
A further issue concerning beta-blocker treatment
is whether and when they can be withdrawn in pa-
tients with stable coronary disease. This issue is dis-
cussed in a broader setting in the following section.
THE NEED FOR TRIALS OF
TREATMENT WITHDRAWAL
Patients with stable coronary disease usually take
many drugs including, for example, aspirin, beta-
blockers, statin, ACE inhibitor, plus other drugs if
they are hypertensive, diabetic, and/or have other
comorbid conditions. In this context, industry-
sponsored trials seeking regulatory approval for a
new class of drugs are often conducted as placebo-
controlled trials in addition to all of these treatments.
Thus, effective new agents may cause an accu-
mulating and potentially excessive polypharmacy,
especially in elderly patients.
One concern is that such trials are of limited
duration, whereas in routine practice, treatments,
both new and established, may be administered
open-endedly over many years. As patients age and
their renal function declines, the potential for
adverse drug interactions and/or drug side effects
arises. The reduced efﬁcacy of some drugs over
longer medication periods is an important issue that
largely remains unexplored research territory. As part
of this broader topic of long-term polypharmacy, we
need clinical trials that can investigate the with-
drawal of certain established medications to see
whether such withdrawal induces patient beneﬁt,
harm, or no difference compared with continued
medication. Which drugs, for which patients, and for
which key outcomes are trials of treatment with-
drawal ripe for investigation?
The long-term effectiveness of beta-blockers has
been questioned. Therefore, a trial of withdrawal of
beta-blocker treatment could be along the following
lines: patients undergoing PCI for stable coronary
disease and who are already on a beta-blocker could
be randomized at their post-procedure follow-up
visit (typically 6 weeks post-PCI) to withdrawal or
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primary endpoint could be all-cause death, myocar-
dial infarction, and hospitalization for heart failure
over 1 year of follow-up. Hypotheses in reference to
the superiority, inferiority, and noninferiority of
withdrawal would all be examined. Data on quality of
life, angina symptoms, adverse events, compliance,
and other cardiac events would also be evaluated.
Another controversial topic is the duration of
dual antiplatelet therapy (e.g., aspirin þ clopidogrel)
administered to patients undergoing PCI with a drug-
eluting stent. Stopping too soon may increase the risk
of stent thrombosis and possibly other cardiac events,
whereas continuing too long accentuates the risk of
bleeding events. This topic has been hotly debated,
with various trials of dual antiplatelet therapy dura-
tion being initiated. DAPT (Dual Antiplatelet Therapy)
(44), the largest of these trials, recruited 20,000
patients, the main comparison being between 12 and
30 months duration, a time comparison now thought
to be less relevant. The real question is whether or
not dual antiplatelet therapy can be administered
for <12 months. OPTIMIZE (Optimized Duration of
Clopidogrel Therapy Following Treatment With the
Endeavor Zotarolimus-Eluting Stent in the Real World
Clinical Practice) (45) is 1 such trial, comparing 3
months versus 12 months of dual antiplatelet therapy
after a zotarolimus-eluting stent in 3,119 patients.
They showed noninferiority for the composite pri-
mary endpoint of death, myocardial infarction,
stroke, or major bleed over 12 months. But, the real
concerns are excess stent thrombosis if dual anti-
platelet therapy is stopped too soon and excess major
bleeding if dual antiplatelet therapy is continued too
long. In OPTIMIZE there were 4 versus 1 stent
thromboses contrasting with 3 versus 6 major bleeds
in the 3- and 12-month dual antiplatelet therapy
groups, respectively. Thus, this trial is too small to
reach deﬁnitive conclusions. We await the ﬁndings of
other trials, several comparing 6 months versus
12 months of dual antiplatelet therapy in over 11,000
total patients receiving a newer generation of stents.
THE IMPORTANCE OF TRIALS INTO
ALTERNATIVE TREATMENT STRATEGIES
In practical terms, RCTs comparing different drugs or
devices (e.g., stents) are often relatively easy to un-
dertake, butmany important therapeutic questions are
more fundamental in that they involve a choice of
substantially different alternative strategies in patient
management. Here, the challenge is to conduct RCTs
of sufﬁcient quality, size, and representativeness. A
common difﬁculty is to successfully recruit sufﬁcientpatients into such strategic trials. Each patient is faced
with 2 markedly different therapeutic options (e.g.,
surgery vs. some alternativemanagement, invasive vs.
conservative management). Therefore, eliciting pa-
tient consent to be randomized is more of a challenge.
Also, recruiting sufﬁcient investigators in a state of
clinical equipoise to accept randomization is no
easy matter, especially when it requires collaboration
across different specialties, for example, surgeons and
interventional cardiologists.
Consider the case of multivessel primary PCI in
STEMI patients. The PRAMI (Preventive Angioplasty
in Myocardial Infarction Trial) (46) identiﬁed on
angiogram those patients to be treated by primary PCI
who also had 1 or more other signiﬁcantly stenosed
arteries in addition to the culprit lesion causing the
myocardial infarction. Such patients were then ran-
domized to either stenting of the culprit lesion only or
to preventive angioplasty, whereby stents were also
placed in other stenosed arteries. This multicenter
U.K. trial took almost 5 years to randomize 465 pa-
tients, reﬂecting recruitment difﬁculties in such
pragmatic trials.
Nevertheless, the interim results showed a marked
treatment beneﬁt of multivessel primary PCI, and the
Data and Safety Monitoring Board recommended that
the PRAMI trial be stopped early for superiority. Over
a mean 23-month follow-up, the composite primary
endpoint (refractory angina, nonfatal myocardial
infarction, and cardiac death) had a hazard ratio of
0.35 (95% CI: 0.21 to 0.58; p < 0.001) in favor of
multivessel versus culprit-vessel–only primary PCI.
Findings for all 3 components of this primary
endpoint were similar, and there was a rapid diver-
gence in risk soon after randomization.
There has been much debate over these ﬁndings.
The apparently huge treatment beneﬁt is based on
rather few primary events (53 vs. 21), and so one feels
that the 65% reduction in hazard is too good to be
true. Also, the trial was terminated early, perhaps on
a “random high,” which may exaggerate the true
beneﬁt. The trial was not blinded, which may
contribute to a potential bias. So, these apparently
impressive ﬁndings are, perhaps, not sufﬁcient to
justify a radical change in the routine management of
STEMI patients with additional stenosed lesions, but
are a motivation for other RCTs of preventive angio-
plasty to be undertaken.
The COMPLETE (Complete vs Culprit-only Revas-
cularisation to Treat Multi-vessel Disease after Pri-
mary PCI for STEMI) trial (47) is also randomizing
patients to revascularization of culprit lesion only
versus a strategy of complete revascularization using
drug-eluting stents of all suitable noninfarct-related
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hospitalization period, rather than simultaneous
with the culprit lesion PCI as was done in the PRAMI
trial. The primary endpoint is restricted to CV death
or new myocardial infarction over a minimum 2 years
of follow-up, and hence, the intended sample size is
3,900 patients. The trial has recently started, and
results are expected in the year 2020. That is a long
time ahead, and one wonders (as in all trials of
lengthy recruitment) whether changes in background
therapies in the interim could negate the generaliza-
tion of trial results to clinical practice.
RCTs VERSUS OBSERVATIONAL REGISTRIES:
WHAT (NOT) TO BELIEVE?
Whether patients with multivessel coronary disease
should receive coronary artery bypass graft (CABG)
or PCI is a challenging question that has stimulated
clinical trials research for over 20 years. The need for
reintervention and the risk of myocardial infarction
is higher after PCI, but the short-term risk of stroke is
higher after CABG, which is, of course, more invasive
and incapacitating for a few weeks. But, the key
issue is whether there is a difference in patient sur-
vival. Table 1 summarizes the variety of evidence
available.
A meta-analysis of 10 older trials of CABG versus
PCI before the use of drug-eluting stents (48) pro-
vided data on 7,812 patients over a median 5.9 years
follow-up. Overall, there was a hint of a survival
beneﬁt for CABG: hazard ratio: 0.91 (p ¼ 0.12). This
became clearer in the subgroup of 1,233 diabeticTABLE 1 Summary of 5-Year Mortality in Both RCTs and
Registries Comparing CABG and PCI
5-Year Mortality
Number of
Patients CABG PCI p Value
10 older trials
All patients 7,812 8.4 10.0 0.12
Diabetic 1,233 12.3 20.0 Interaction
Nondiabetic 6,561 7.5 8.1 0.014
SYNTAX 1,800 11.4 13.9 0.10
FREEDOM all diabetic 1,900 10.9 16.3 0.049
ASCERT registry† 189,793 16.4* 20.8* 0.000001
CMS registry†
All patients 210,312 25.9 28.1 0.000001
Diabetic 30.4 33.9 Interaction
Nondiabetic 23.8 25.3 0.002
Values are % unless otherwise indicated. *4-year mortality. †Mortality rates are
higher in the 2 registries, mainly because they only include patients age >65 years.
CABG¼ coronary artery bypass graft; PCI¼ percutaneous coronary intervention;
RCT ¼ randomized controlled trial.patients (hazard ratio: 0.70) compared with non-
diabetic subjects (hazard ratio: 0.98), interaction
p ¼ 0.014.
However, this needs updating to reﬂect the mod-
ern use of drug-eluting stents. Thus far, there are 2
such published trials: SYNTAX (SYNergy Between
PCI With TAXUS and Cardiac Surgery) (49) in 1,800
patients with 3-vessel or left main disease, and
FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease) (50) in 1,900 diabetic
patients with multivessel disease. Both trials show
5-year mortality trends favoring CABG: SYNTAX
11.4% versus 13.9% (p ¼ 0.10); and FREEDOM 10.9%
versus 16.3% (p ¼ 0.049), but this leaves considerable
uncertainty with wide CIs around the effect estimates.
We await ﬁndings from the EXCEL (Evaluation of
Xience Prime or Xience V versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revas-
cularization) trial (51), which, although intended to
recruit 2,600 patients, has, at the sponsor’s request,
recently curtailed recruitment at 1,905 patients, with
primary results anticipated in 2016. Note that no trial
of CABG versus PCI has ever recruited more than
2,000 patients. Such trials demand collaboration be-
tween cardiac surgeons and interventional cardiolo-
gists in each center regarding who is eligible for either
procedure, and given the contrasting nature of the 2
procedures, the approach to eliciting informed patient
consent is a challenge. Hence, there is always valid
concern as to whether the patients in these trials are
sufﬁciently representative of the broader population
of patients in routine practice. A few trials (e.g., BARI
[Bypass Angioplasty Revascularization Investigation])
(52) have included registries of nonrandomized pa-
tients to address this issue. Overall, limited size and
doubts regarding their generalizability are often pre-
sent when interpreting such trials of alternative
strategies.
Comparative effectiveness studies based on
observational registries provide a very different
approach and show mortality differences between
CABG and PCI in patients with multivessel disease.
The ASCERT (ACCF and STS Database Collaboration
on the Comparative Effectiveness of Revasculariza-
tion Strategies) registry (53) compared 86,244 CABG
patients with 103,549 PCI patients age $65 years over
a median 2.67 years of follow-up. Adjustment for
potential confounders was done using a propensity
score with inverse probability weighting, giving
adjusted 4-year mortality rates of 16.4% versus
20.8%, hazard ratio: 0.79 (95% CI: 0.76 to 0.82;
p < 0.00000001). An alternative approach by
Hlatky et al. (54) studied Medicare beneﬁciaries
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matched pairs of CABG/PCI patients with a median
4.3 years follow-up. Five-year mortality rates were
25.9% versus 28.1%, hazard ratio: 0.92 (95% CI: 0.90
to 0.95; p < 0.00000001). Both studies suggest a very
highly-signiﬁcant survival beneﬁt for CABG, but the
sizes of these effects differ enormously: comparing
the 2 hazard ratios, 0.79 and 0.92, the interaction test
has p < 0.01. So, we have very precise estimates from
2 very large registries that differ substantially in
magnitude. Can either of them be trusted?
The problem with all such comparative effective-
ness studies is that, in the absence of random allo-
cation, there is potentially strong selection bias as
to which patients get which treatments (55,56).
Although propensity score or covariate adjustment
methods can adjust for measured confounders, it
would be naive to assume that potential residual con-
founding (i.e., bias) does not exist. One cannot expectthe database to capture all of the complex reasons
why one patient gets CABG and another gets PCI.
Of interest are the exploratory subgroup analyses
for diabetes in Hlatky et al. (54). For diabetic and
nondiabetic patients, the hazard ratios were 0.88
and 0.95, respectively (interaction p ¼ 0.002). This
is broadly compatible with ﬁndings from the
meta-analysis of older trials mentioned previously.
Perhaps the survival beneﬁt of CABG is truly more
pronounced in diabetic patients, although with
modern-day practice (drug-eluting stents), the gap
may have narrowed. The issue may be clouded
further by the emergence of an ever-newer genera-
tion of drug-eluting stents, as in EXCEL, but not
SYNTAX and FREEDOM (57). In any ﬁeld character-
ized by rapid technological changes and in which
trials require prolonged follow-up, perhaps every trial
is vulnerable to the accusation of “obsolescence” by
the time it is published, but this does not obviate the
rationale for such trials.
Although the data from registries may be more
applicable to clinical practice at large, they are sub-
ject to selection bias. RCTs are, however, subject to
“entry bias,” in that patients are highly selected on
the basis of clinical equipoise with regard to the
ﬁndings on angiography. Registries and trials may
complement each other and emphasize differences
between the process of randomization versus the
selection of a therapeutic strategy based upon
physician judgment and patient preference (52). Note
that in the EAST (Emory Angioplasty versus Surgery
Trial) trial of percutaneous transluminal coronary
angioplasty versus coronary bypass surgery, college-
educated patients were less likely to accept randomi-
zation (58).
We need to be continually cautious of making
therapeutic claims from observational data. For
instance, a meta-analysis of 21 randomized trials (59)
comparing drug-eluting and bare-metal stents in
8,867 patients with mean 2.9 years follow-up found
no difference in mortality: hazard ratio: 0.97
(p ¼ 0.72). The corresponding meta-analysis of 31
observational registries had far more patients,
169,595 with mean 2.5 years follow-up, and revealed
signiﬁcantly lower mortality after a drug-eluting
stent: hazard ratio: 0.81 (p < 0.00001).
All observational studies are vulnerable to the in-
ﬂuence of confounding variables. In this respect,
randomized controlled trials are crucial. This is
exempliﬁed by the epidemiologic data that demon-
strated a protective effect of estrogen on the heart
and bone (60). In contrast, data from the Women’s
Health Initiative (61,62), a set of 2 hormone therapy
trials in healthy post-menopausal women, showed a
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1627number of adverse outcomes, including an excess risk
of coronary heart disease, stroke, venous thrombo-
embolism, and breast cancer. Similar examples of
epidemiological evidence and biological plausibility
that did not withstand the rigorous scrutiny of RCTs
are provided by studies of vitamin C, vitamin E, and
beta-carotene.
Thus, observational research has its uses, but can
sometimes be prone to make false claims on the
relative efﬁcacy and relative safety of alternative
treatments.
CONCLUSIONS
This paper is not meant to be a comprehensive re-
view of the whole ﬁeld of clinical trials researchapplied to cardiology. Rather, it has attempted to
highlight several important controversies and chal-
lenges. The Central Illustration summarizes the issues
that were tackled. Although we have much to cele-
brate in the past achievements of cardiology trials
in generating many important treatment advances,
there remains considerable room for improvement
if future RCTs are truly to achieve their full potential
in enhancing public health and optimizing cardio-
logical patient care.
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